A5019201961- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Cervical Cancer and HPV Research
- Immune responses and vaccinations
- Influenza Virus Research Studies
- Global Maternal and Child Health
- Tuberculosis Research and Epidemiology
- Virology and Viral Diseases
- Hepatitis B Virus Studies
- HIV/AIDS Impact and Responses
- Hepatitis Viruses Studies and Epidemiology
- Genital Health and Disease
- Viral Infections and Outbreaks Research
- SARS-CoV-2 and COVID-19 Research
- Child Nutrition and Water Access
- Global Cancer Incidence and Screening
- Endometrial and Cervical Cancer Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Pneumonia and Respiratory Infections
- Healthcare Systems and Reforms
- Viral gastroenteritis research and epidemiology
- Global Health Care Issues
- Poverty, Education, and Child Welfare
- Global Health and Epidemiology
- Streptococcal Infections and Treatments
Boston University
2023-2024
Harvard University
2021-2024
Management Sciences for Health
2023
Center for Surveillance, Epidemiology, and Laboratory Services
2021-2022
AID Atlanta
2022
Beth Israel Deaconess Medical Center
2022
Massachusetts Mental Health Center
2022
University of York
2021
University of Maryland, College Park
2021
Weatherford College
2021
An analysis of return on investment can help policy makers support, optimize, and advocate for the expansion immunization programs in world’s poorest countries. We assessed associated with achieving projected coverage levels vaccinations to prevent diseases related ten antigens ninety-four low- middle-income countries during 2011–20, Decade Vaccines. derived these estimates by using costs vaccines, supply chains, service delivery their economic benefits. Based illnesses averted, we estimated...
BackgroundIntroduction of human papillomavirus (HPV) vaccination in settings with the highest burden HPV is not universal, partly because absence quantitative estimates country-specific effects on health and economic costs. We aimed to develop validate a simple generic model such that could be used understood range little external support.MethodsWe developed Papillomavirus Rapid Interface for Modelling Economics (PRIME) assess cost-effectiveness girls against before sexual debut terms...
Measles is a highly contagious, vaccine-preventable disease that requires high population immunity for transmission to be interrupted. All six World Health Organization regions have committed eliminating measles; however, no region has achieved and sustained measles elimination. This report describes elimination progress during 2000-2022. During 2000-2019, estimated coverage worldwide with the first dose of measles-containing vaccine (MCV) increased from 72% 86%, then declined 81% in 2021...
In 2012, the World Health Assembly endorsed Global Vaccine Action Plan,* with objective of eliminating measles
All six World Health Organization (WHO) regions have committed to eliminating measles.* The Immunization Agenda 2021-2030 (IA2030)
Vaccines save thousands of lives in the United States every year, but many adults remain unvaccinated. Low rates vaccine uptake lead to costs individuals and society terms deaths disabilities, which are avoidable, they create economic losses from doctor visits, hospitalizations, lost income. To identify magnitude this problem, we calculated current burden that is attributable vaccine-preventable diseases among US adults. We estimated total remaining at approximately $9 billion (plausibility...
To estimate the economic impact likely to be achieved by efforts vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- middle-income countries largely supported Gavi, Vaccine Alliance.We used health models of achieving forecasted coverages for vaccination Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae yellow fever. In comparison with...
Vaccination is one of the most effective public health interventions. We investigate impact vaccination activities for
Abstract Background To eliminate cervical cancer as a public health problem, the World Health Organization had recommended routine vaccination of adolescent girls with two doses human papillomavirus (HPV) vaccine before sexual initiation. However, many countries have yet to implement HPV because financial or logistical barriers delivering outside infant immunisation programme. Methods Using three independent transmission models, we estimated long-term benefits and cost-effectiveness one-dose...
Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe effective TB vaccines that can rapidly reduce disease burden are essential for achieving elimination. We assessed future costs, cost-savings, cost-effectiveness of introducing novel in low- middle-income countries (LMICs) a range product characteristics delivery strategies.
BackgroundTuberculosis is a leading infectious cause of death worldwide. Novel vaccines will be required to reach global targets and reverse setbacks resulting from the COVID-19 pandemic. We estimated impact novel tuberculosis in low-income middle-income countries (LMICs) several delivery scenarios.MethodsWe calibrated model 105 LMICs (accounting for 93% incidence). Vaccine scenarios were implemented as base-case (routine vaccination those aged 9 years one-off 10 older, with country-specific...
Measles supplementary immunization activities (SIAs) are vaccination campaigns that supplement routine programs with a recommended second dose opportunity to children of different ages regardless their previous history measles vaccination. They conducted every 2–4 years and over few weeks in many low- middle-income countries. While SIAs have high coverage, it is unclear whether they reach the who miss vaccine dose. Determining reached by vital understanding effectiveness, as well measure...
BackgroundThere have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This disruption led under-immunised cohorts and interrupted progress reducing vaccine-preventable disease burden. There have, so far, few studies of effects on vaccine effects. We aimed quantify vaccine-coverage routine campaign services, identify regions that could particularly benefit from catch-up activities, establish if losses effect be...
Abstract Background To plan for the financial sustainability of immunization programs and make informed decisions to improve coverage equity, decision-makers need know how much these cost beyond vaccine. Non-vaccine delivery estimates can significantly influence cost-effectiveness used allocate resources at country level. However, many low- middle-income countries (LMICs) do not have unit available, or that are uncertain, unreliable, old. We undertook a Bayesian evidence synthesis generate...
Most individuals developing tuberculosis (TB) are working age adults living in low- and middle-income countries (LMICs). The resulting disability death impact economic productivity burden health systems. New TB vaccine products may reduce this burden. In study, we estimated the of introducing novel vaccines on gross domestic product (GDP) growth 105 LMICs.
India had an estimated 2.9 million tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective adolescents adults could reduce this burden. M72/AS01
Following the global call for action by World Health Organization to eliminate cervical cancer (CC), we evaluated how each CC policy decision in Norway influenced timing of elimination, and whether introducing nonavalent human papillomavirus (HPV) vaccine would accelerate elimination be cost-effective. We used a multi-modeling approach that captured HPV transmission carcinogenesis estimate incidence associated with six past future prevention decisions compared pre-vaccination scenario...
One in two patients developing tuberculosis (TB) low-income and middle-income countries (LMICs) faces catastrophic household costs. We assessed the potential financial risk protection from introducing novel TB vaccines, how health economic benefits would be distributed across income quintiles.
Tuberculosis remains a major public health problem in South Africa, with an estimated 300,000 cases and 55,000 deaths 2021. New tuberculosis vaccines could play important role reducing this burden. Phase IIb trials have suggested efficacy of the M72/AS01E vaccine candidate BCG-revaccination. The potential population impact these is unknown. We used age-stratified transmission model tuberculosis, calibrated to epidemiological data from estimate economic vaccination simulated scenarios over...